OF THE INVENTION LOCAL ADMINISTRATION OF RIPK2 INHIBITORS FOR THE
CURATIVE TREATMENT OF
ALLERGIC ASTHMA The present invention relates to a method for use in the treatment of
Asthma. Here, the inventors identified the
receptor-interacting
serine / threonione
protein kinas 2 (RIPK2) as a novel therapeutic target to improve
Asthma-related diseases. They demonstrated that a local preventive administration of the RIPK2 inhibitor reduced AHR,
airway eosinophilia,
mucus production, Th2 cytokines and the alarmin IL-33. Moreover, they demonstrated the early role of IL-33 in the NOD1-dependent response of the
epithelium to HDM. Therefore, the inventors demonstrated that the local interference of the NOD1 signaling pathway through RIPK2 inhibition may represent a new
therapeutic approach in
asthma. Other pulmonary diseases could also benefit of this treatment. Thus, the present invention relates to a method for use in the
curative treatment of HDM-induced
asthma comprising administrating to a subject in need thereof a therapeutically effective amount of an inhibitor of RIPK2.